Milner Therapeutics Institute to house world-class functional genomics laboratory, in new partnership with AstraZeneca and the Medical Research Council
We are delighted to announce a new partnership with AstraZeneca and the Medical Research Council (MRC) that will establish a new state-of-the-art functional genomics laboratory at the Milner Therapeutics Institute. This marks a significant step forward in our mission...
Pathania collaboration awarded £1.5m to research childhood brain tumours
We are delighted to share that the Pathania Lab join a team of researchers who have been awarded £1.5 million in The Brain Tumour Charity’s Quest for Cures grant. Dr Manav Pathania and his group – who are based at the Milner Institute – join researchers from...
Takeda and Sanofi join Milner Therapeutics Consortium
We are excited to announce that two new pharma partners — Takeda and Sanofi — have joined the Milner Consortium in the past month. Now with 14 pharma partners and 3 academic partners, this is the largest cross-sector Biomedical Consortia in the UK that is working in...
A full house at eighth Milner Therapeutics Symposium
We were excited to welcome ∼500 delegates at West Road Concert Hall for our annual Symposium on July 5th, with a further 300+ UK and international delegates opting to view the talks online. A small selection of photographs can already be found on our website, with...
Multiple Milner affiliates recognised at Cambridge Independent Science and Technology Awards
We are delighted that several of our affiliated companies were recognised at the 2023 Cambridge Independent Science & Technology Awards last night. Among the list of awardees was Cardiatec Biosciences, an AI drug target discovery company co-founded by Milner Head...
Dr Cathy Tralau-Stewart appointed Executive Director of the Milner Therapeutics Institute
We are delighted to welcome Dr Cathy Tralau-Stewart as the new Executive Director at the Milner Therapeutics Institute. Cathy will work alongside Director Tony Kouzarides and the Milner team to lead and deliver our vision to transform pioneering science into...
Milner welcomes new Head of Target Discovery
We are delighted to welcome Dr Erica Bello as the new Head of Target Discovery at the Milner Therapeutics Institute. Erica brings to the team broad experience in CRISPR screening and advanced disease models, both from her work at the Wellcome Sanger Institute and more...
Milner Institute collaborates to launch Cambridge AI Club for Biomedicine
The AI Club for Biomedicine, launched earlier this month, is a new initiative created to bring together the biomedical AI and machine learning community in Cambridge. This collaboration between the Milner and CRUK Cambridge Institute will be held on the first Thursday...